Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-22T23:08:26.683Z Has data issue: false hasContentIssue false
  • English
  • Français

The Value and Limitations of Chlorpromazine in the Treatment of Anxiety States

Published online by Cambridge University Press:  08 February 2018

W. Linford Rees  and
Carl Lambert
W. Linford Rees
Affiliation:
Royal Bethlem and Maudsley Hospitals
Get access Rights & Permissions [Opens in a new window]

Extract

Chlorpromazine hydrochloride (Largactil) introduced by Laborit (1952) has aroused considerable interest on account of its varied pharmacodynamic actions and clinical reports drawing attention to its possible use in anaesthesia, general medicine and psychiatry.

Chemically related to certain antihistamine drugs, it has little antihistaminic activity itself but has diverse effects on the nervous system. It is a neural depressant with central and peripheral action, vagolytic and sympatholytic properties. (Chauchard, 1952; Courvoisier, 1953; Sigwald and Boutier, 1953; Staehelin and Kielholz, 1953; Lehrman and Hanrahan, 1954; Anton-Stephens, 1954; Winkelman, 1954; Garmany, 1954; and Elkes and Elkes, 1954.)

Enthusiastic claims have been made regarding the therapeutic value of chlorpromazine in a wide variety of psychiatric disorders; many of these have failed to carry conviction, as most of the reports are based on mixed groups with an insufficient number of patients in each diagnostic category to justify definite conclusions and also because controlled procedures were rarely used.

We therefore decided to confine our investigation to one type of psychiatric disorder and chose anxiety states, since the reported pharmacodynamic actions of the drug suggested that it might be of value in the treatment of states of anxiety and tension. The total group studied consists of 150 patients all of whom are treated as out-patients.

Type
Original Articles
Information
Journal of Mental Science , Volume 101 , Issue 425 , October 1955 , pp. 834 - 840
Copyright
Copyright © Royal College of Psychiatrists, 1955 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anton-Stephens, D., J. Ment. Sci., 1954, 100, 543.Google Scholar
Chauchard, B., and Chauchard, P., Presse Médicale; 1952, 60, 78, 1674.Google Scholar
Courvoisier, S., Fournel, J., Ducrot, R., Kolsky, M., and Koutschet, R., Arch. int. Pharmacodyn., 1953, 92, 305.Google Scholar
Elkes, J., and Elkes, C., Brit. med. J., 1954, ii, 560.CrossRefGoogle Scholar
Garmany, G., May, D. R., and Folkson, A., Brit. med. J., 1954, ii, 439.Google Scholar
Laborit, H., Huguenard, P., and Alluaume, R., Presse Médicale, 1952, 60, 206.Google Scholar
Lehmann, H. E., and Hanrahan, G. E., Arch. Neurol. Psychiat., Chicago, 1954, 71, 227.Google Scholar
Sigwald, J., and Bouttier, D., Ann. Med., 1953, 54, 150.Google Scholar
Staeheun, J. E., and Kielholz, P., Schweiz, med. Wschr., 1953, 83, 581.Google Scholar
Winkelman, N. W., J. Amer. med. Ass., 1954, 155, 18.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.